• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, September 12, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Plan A is to get patients to stick to their blood pressure pills

Bioengineer by Bioengineer
January 19, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them. This advice is given to clinicians by Julie Lauffenburger and colleagues of the Brigham and Women's Hospital and Harvard Medical School. In a paper¹ in the Journal of General Internal Medicine², published by Springer, the researchers found more value in fixed-dose combination pills that contain more than one type of medication, rather than separate pills for each drug.

The researchers evaluated data from claims submitted to a large national health insurer between 2009 and 2013. It included information from patients who had started using anti-hypertensive medication during this period to help lower their blood pressure. In all, 78,958 of those in the sample of 484,493 patients were started off on fixed-dose combinations (meaning that they took a single pill containing multiple drugs). A further 383,269 were prescribed a single therapy (only one type of medicine per pill), and 22,266 multi-pill combinations (two or more different anti-hypertensive tablets or capsules).

Fixed-dose combinations were found to work best to help patients keep on taking their anti-hypertensive medicines regularly. Such patients were 9 percent more likely to be persistent in taking their blood pressure pill, while they were also 13 percent more likely to regularly use the treatment prescribed to them than patients who began using single anti-hypertensive therapy.

The findings also highlighted other factors that play a role in the type of treatment being prescribed, and the chances of people ultimately adhering to and persevering in taking their medication. Patients who started off on single therapies or multi-pill combinations were, for instance, generally sicker and more likely to regularly seek further medical help than those on fixed-dose combinations. They were also slightly less likely to refill their prescriptions. Those being prescribed fixed-dose combinations were generally older and female.

"Fixed-dose combination pills appear to enhance adherence and persistence to anti-hypertensive medications among commercially insured patients starting treatment compared with single therapy," says Lauffenburger, in summarizing the findings. "For patients beginning anti-hypertensive treatment, clinicians may therefore want to consider starting patients on a fixed-dose combination pill rather than a single therapy."

###

References:

1. Lauffenburger, J.C. et al. (2017). Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study, Journal of General Internal Medicine. DOI 10.1007/s11606-016-3972-z

2. The Journal of General Internal Medicine is the official journal of the Society of General Internal Medicine.

Media Contact

Christina Theis
[email protected]
49-622-148-78414
@SpringerNature

http://www.springer.com

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Nanomedicine: A New Frontier in Targeting Metastasis

September 12, 2025
blank

Fungal Effector Undermines Maize Immunity by Targeting ZmLecRK1

September 12, 2025

New Phthalide Compounds Show Promise as Antifungal Agents

September 12, 2025

Overcoming Challenges in Treating Severe Eating Disorders

September 12, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    152 shares
    Share 61 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    64 shares
    Share 26 Tweet 16
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Nanomedicine: A New Frontier in Targeting Metastasis

Fungal Effector Undermines Maize Immunity by Targeting ZmLecRK1

New Phthalide Compounds Show Promise as Antifungal Agents

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.